MELD 3.0 Score
MELD 3.0 — updated MELD incorporating sex-specific factor and albumin. Improves survival prediction in women and those with low albumin. Replaces MELD-Na for organ allocation in some centres.
Score interpretation
→ MELD 3.0 <10: Very low 90-day mortality risk. Continue medical management; review for optimisation of complications (ascites, HE, varices). Not a transplant priority.
→ MELD 3.0 10–19: Moderate disease severity. Liver transplant listing evaluation; treat complications aggressively; hepatology review monthly; SBP prophylaxis; beta-blockers for varices.
→ MELD 3.0 20–29: High mortality risk. Priority liver transplant listing; TIPS consideration for refractory ascites/varices; nephrology involvement for HRS; close follow-up.
→ MELD 3.0 ≥30: Very high mortality risk. Urgent liver transplant evaluation; intensive care if AKI/HRS; palliative care discussion if not transplant candidate; goals of care.
Interpretation bands for the MELD 3.0. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Maddrey's Discriminant Function for Alcoholic Hepatitis · Hepatology
- Lille Model for Alcoholic Hepatitis · Hepatology
- NAFLD Fibrosis Score · Hepatology
- AST to Platelet Ratio Index (APRI) · Hepatology
- West Haven Criteria for Hepatic Encephalopathy · Hepatology
- EVendo Score for Oesophageal Varices · Hepatology
- Digoxin-specific Antibody Fragments (DigiFab) · Antidote
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Idarucizumab (Praxbind) · Dabigatran reversal agent (specific antidote)
- Digoxin-specific Antibody Fragments (DigiFab) · Antidote
- Digoxin-specific antibody fragments · Digoxin antidote (Fab fragments)
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.